Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genscript Biotech ( (HK:1548) ) has shared an update.
Legend Biotech, an associate of Genscript Biotech, announced that its product CARVYKTI® generated approximately $439 million in net trade sales for the quarter ending June 30, 2025. This financial performance is linked to a collaboration with Janssen Biotech, highlighting the product’s market success and potential impact on Genscript’s financial standing and industry positioning.
More about Genscript Biotech
Genscript Biotech Corporation, incorporated in the Cayman Islands, operates in the biotechnology industry. The company is associated with Legend Biotech Corporation, which is involved in the development of pharmaceutical products and is listed on the Nasdaq Global Select Market in the U.S.
Average Trading Volume: 24,957,436
Technical Sentiment Signal: Buy
Current Market Cap: HK$32.93B
Learn more about 1548 stock on TipRanks’ Stock Analysis page.